stockrow
Saturday 7 November 2026
Export KLRA’s income statement to Excel — free account
Kailera Therapeutics, Inc.
KLRA Healthcare Biotechnology
- EPS
- +100.0%
- Free cash flow
- −326.0%
Quarter to September 2026, against a year earlier
12.97
0.80
+6.57%
Follow KLRA
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
21.84 | 11.11 | 9.67 | 12.01 |
+4 more quarters Free account |
Net Debt/EBITDA |
8.49 | 7.56 | 6.14 | 8.15 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | — | |
Operating CF/Net income |
1.40 | 0.70 | 0.87 | 0.74 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (13.48) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Free Cash Flow per Share |
(1.03) | (0.76) | (3,162.50) | (238,625.00) | |
Cash per Share |
6.95 | 8.97 | 24,035.83 | 2,730,280.00 | |
Shareholders Equity per Share |
7.95 | 10.94 | 25,938.70 | 3,179,530.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.95 | 10.94 | 25,938.70 | 3,179,530.00 | |
Free Cash Flow |
(133.67) | (77.53) | (68.31) | (47.72) | |
Working Capital |
877.64 | 845.52 | 475.48 | 511.13 | |
Capital Expenditures |
— | — | — | (1.64) | |
Net Current Asset Value |
868.69 | 836.22 | 465.84 | 501.15 | |
| Other line items | |||||
Quick Ratio |
21.40 | 10.96 | 9.47 | 11.77 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.03) | (0.76) | (3,162.50) | (230,400.00) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (8,225.00) | |
Average Payables |
5.72 | — | — | — | |
Average Assets |
630.31 | 605.71 | 401.60 | — | |
Average Common Equity |
406.17 | — | — | — | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026